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Abstract
Background: Adipokines are related to knee osteoarthritis, but their exact role is not well known. The aim of this
study was to evaluate the association between adipokines in synovial fluid and clinical severity in patients with
knee osteoarthritis with joint effusion.
Methods: Cross-sectional study with systematic inclusion of female patients with symptomatic primary knee
osteoarthritis with ultrasound-confirmed joint effusion. Age, physical exercise, knee osteoarthritis symptoms duration,
classical cardiovascular risk factors and different anthropometric measurements were collected. Metabolic syndrome
was defined in accordance to National Cholesterol Education Program-Adult Treatment Panel III. Radiographic severity
was evaluated according to Kellgren-Lawrence scale and Lequesne index was used to assess clinical severity. Seven
adipokines (leptin, adiponectin, resistin, visfatin, osteopontin, omentin and chemerin) and three inflammatory markers
(tumor necrosis factor α, interleukin 6 and high sensitivity C-reactive protein) were measured by enzyme-linked
immunosorbent assay in synovial fluid.
Results: Kellgren-Lawrence grade, physical exercise, all anthropometric measurements (especially waist circumference),
tumor necrosis factor α, and high levels of leptin, resistin, and ostepontin were related to knee osteoarthritis severity.
After adjustment for clinical confounders (age, symptom duration, and radiology), anthropometric measurements,
inflammatory markers, and all evaluated adipokines, there were independent associations with clinical severity for
resistin (directly associated) and visfatin (inversely associated). No other adipokines or inflammatory markers were
independently associated with Lequesne index. The association of radiological parameters, physical exercise, and
waist circumference with Lequesne index remained after adjustment.
Conclusions: Resistin was directly associated, and visfatin was inversely associated, with clinical severity in female
patients with knee osteoarthritis with joint effusion. These associations were more important after adjustment for
confounders, especially when all adipokines were evaluated.
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Background
Osteoarthritis (OA) is the most prevalent articular disease,
and the most common cause of disability in developed
and developing countries [1], with knee involvement being
the most prevalent and disabling condition [2]. The preva-
lence of knee osteoarthritis (KOA) increases with age,
and, given the aging of population, an even greater impact
is expected in the future [3]. The etiology of OA is multi-
factorial, classically related to mechanical factors, trauma,
or overload [2]. Genetic and, more recently, anthropomet-
ric, metabolic, and local inflammatory factors have been
implicated in the pathophysiology of OA [4]. Different
epidemiologic studies have shown a high prevalence of
cardiovascular risk factors, such as hypertension, dyslipid-
emia, diabetes, obesity, and metabolic syndrome (MetS),
in patients with KOA [5, 6]. MetS and its individual com-
ponents are related to severity as measured by pain, dis-
ability, and radiography [7]. More recently, some authors
have suggested that OA and MetS share a similar bio-
chemical and inflammatory profile, which could explain
associations between them and their influence in the se-
verity or progression of the disease [8]. Obesity is, together
with age, the most important risk factor related to KOA
[9, 10]. In this respect, adipokines such as leptin, adipo-
nectin, resistin, visfatin, and osteopontin, both in plasma
and in synovial fluid, have been associated with the
frequency and severity of KOA, usually measured by
radiographic damage. However, studies of adipokines in
synovial fluid were performed in patients with advanced
disease undergoing prosthetic surgery and were not
focused on severity or on the inflammatory profile of
KOA [11–17].
Markers of inflammation in synovial fluid, such as
interleukin (IL)-6, tumor necrosis factor α (TNF-α), or
high-sensitivity C-reactive protein (hs-CRP), have been
associated with severity in KOA in recent studies
[18, 19]. In fact, a significant percentage of patients with
KOA present with joint effusion, which could be consid-
ered as a marker of local inflammation. Patients with
KOA with persisting joint effusion could be a particular
subset of KOA with special characteristics compared with
patients without effusion. These patients make up a group
of patients of particular interest in investigations of
metabolic inflammation in KOA.
The exact role of adipokines in KOA is not well
known, but they may play a significant role indirectly via
their link to obesity and directly on OA pathways in
many patients. Researchers in different studies have eval-
uated the relationship between adipokines individually
or controlled by some metabolic and other cytokines
and clinical severity, but they did not assess the possible
interactions when a significant number of adipokines
were evaluated or their relationship to local inflamma-
tion. The main aim of this study was to evaluate the
association of synovial adipokines with clinical severity
in patients with KOA and persistent joint effusion. For
this purpose, the effect on clinical severity and the
biological interactions of adipokines previously studied
in KOA were investigated.
Methods
Patients and study design
We conducted a cross-sectional study with systematic
inclusion of female patients with symptomatic primary
KOA according to American College of Rheumatology
criteria [20] who visited our hospital for a monographic
OA consultation. The women were aged 50–85 years
and had evidence of significant joint effusion based on
physical examination and confirmed by ultrasound
(≥4 mm on midline suprapatellar line). Symptomatic OA
was defined as pain intensity rated as ≥4 on a 10-cm vis-
ual analogue scale despite the use of prescribed analgesic
drugs for at least 3 months. Only patients reporting
persisting knee effusion or with documented effusion in
several consultations were entered into the study.
Patients with secondary OA were excluded, such as those
with a history of trauma, meniscal injury, inflammatory
rheumatic or septic conditions, previous knee surgery, any
condition that could interfere with pain perception, sys-
temic glucocorticoid intake in the last 6 months, or intra-
articular glucocorticoid or hyaluronic acid injection in the
last 3 or 6 months, respectively. The recruitment period
was October 2013 to June 2015. We included only female
patients to homogenize the sample, as there are dif-
ferences between men and women related to pain per-
ception, anthropometric measures, and fat content and
distribution that might influence the adipokine profile
[21–23]. This study was approved by the local ethics com-
mittee at the Parc Tauli Sabadell University Hospital. All
patients included were verbally informed about the study
and signed informed consent forms.
Assessments
Information on the following variables was collected:
age, physical exercise (never, occasional [less than
150 minutes per week], or regular), tobacco exposure,
and KOA symptom duration. Each participant’s medical
history, specifically regarding the presence of cardiovas-
cular risk factors, was recorded. A diagnosis of hyperten-
sion, dyslipidemia, or diabetes was established if already
diagnosed or if the participant was receiving treatment
for any of these conditions. Anthropometric measure-
ments included weight (kg), height (cm), body mass
index (BMI) (kg/m2), waist circumference (WC) (cm),
hip circumference (cm), waist-to-hip ratio (WHR), and
percentage of body fat measured using a bioimpedance
analyzer (BC-418 MA; Tanita, Arlington Heights, IL,
USA) according to a standard protocol. Obesity was
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defined as a BMI ≥30 kg/m2. In accordance with the
modified criteria of the National Cholesterol Education
Program Adult Treatment Panel III, MetS was defined as
having three or more of the following conditions: fasting
plasma glucose ≥100 mg/dl or treatment with glucose-
lowering drugs, arterial blood pressure ≥130/85 mmHg
or antihypertensive medication, fasting plasma triglyc-
erides ≥150 mg/dl (1.7 mmol/L) or drug treatment for
hypertriglyceridemia, high-density lipoprotein (HDL) chol-
esterol <50 mg/dl (1.28 mmol/L) or drug therapy to raise
HDL cholesterol concentration, and WC ≥88 cm [24].
Radiographic severity was evaluated by anteroposterior
knee x-ray examination with the patient in standing pos-
ition performed in the last 18 months and graded accord-
ing to the Kellgren-Lawrence (KL) scale (grades 1–4).
Time between radiologic evaluation and visit was consid-
ered for adjustment in the statistical analysis. Two rheuma-
tologists (JC, CO) evaluated x-rays independently. The
Lequesne algofunctional index, a simple and validated
questionnaire for pain and disability in KOA with scores
ranging from 0 (best) to 24 (worst), was used to assess clin-
ical severity.
Joint aspiration was performed during the visit and at
the same time of the day for proper evaluation of synovial
adipokines. Synovial fluid was analyzed to ensure nonin-
flammatory fluid (joint cell count <2500 cells) and absence
of microcrystals. Synovial samples were stored at −80 °C.
Seven adipokines and three inflammatory markers were
measured by enzyme-linked immunosorbent assay (ELISA)
in accordance with the manufacturers’ recommendations
for synovial fluid dilutions: leptin (Biocompare, South San
Francisco, CA, USA), adiponectin (eBioscience, San Diego,
CA, USA), resistin (RayBiotech, Norcross, GA, USA), osteo-
pontin (eBioscience), visfatin (Phoenix Pharmaceuticals,
Burlingame, CA, USA), omentin (CUSABIO, Wuhan,
China), chemerin (Elabscience, Bethesda, MD, USA),
hs-CRP (DRG Diagnostics, Marburg, Germany), and IL-6
and TNF-α (Milliplex HCYTOMAG-60 K-03; Merck
Millipore, Billerica, MA, USA) (see Additional file 1 for
detailed description). For technical reasons related to
ELISA technology (configuration of the plates used), none
of these markers could be assessed at the same time for all
patients. In order to control for technical variability, the
rounds of measurement were considered as an adjustment
factor in the statistical analyses.
Statistical methods
Clinical data and laboratory parameters and their associ-
ation with Lequesne index score were summarized using
nonparametric methods. Medians, interquartile ranges,
and Spearman’s correlations (r) were used for continu-
ous measures, while frequencies and Mann-Whitney or
Kruskal-Wallis tests were applied to categorical vari-
ables. For estimation of adjusted effects, linear models
were fitted with suitable transformation of explanatory
variables when necessary in order to fit the model as-
sumptions. The covariates included in the multivariate
analyses were age at recruitment, KL grade, time from
visit to date of radiologic assessment, and KOA symp-
tom duration. Using this model as a starting point, a
stepwise algorithm was used sequentially with the rest
of the potential confounders in two stages: first, only
anthropometric and metabolic parameters were evalu-
ated; second, inflammatory markers were considered in
the resulting model, then each adipokine was added
one at a time to the resulting model to assess its associ-
ation with KOA severity (Table 3, “Adjusted effects”
column). Finally, all adipokines were added to the
model to assess their association with the Lequesne
index after controlling for the anthropometric, meta-
bolic, and inflammatory markers found to be inform-
ative in the previous steps, as well as for the rest of the
adipokines (“Multivariate model” column in Table 3).
For interpretation purposes, the partial correlation co-
efficient (PCC) was used as a measure of association for
continuous variables. Associations for adipokines and
inflammatory markers were adjusted by measurement
round in all cases. Owing to high collinearity observed
between adiponectin and omentin (PCC 0.792), only
one of them at a time was included in a linear model.
When selection of confounders was needed, a stepwise
algorithm was carried out using Akaike’s information
criterion for model selection. Associations were
assessed in the linear models using the corresponding F
and Wald tests. Tests were performed at the 5 % sig-
nificance level. All statistical analyses were conducted
using R software (see Additional file 2 for detailed
description).
Results
One hundred fifteen women were included (Table 1).
The percentages of obesity and dyslipidemia were 57.4 %
and 47.8 %, respectively. The prevalence of MetS was
40.9 %. The median BMI, WC, and WHR were in the
obesity range (30.5 kg/m2, 100.5 cm, and 0.91, respect-
ively). The median Lequesne index score was 14. The
predominant KL grades were 2 and 3 (41.7 % each), and
only 3.5 % of our sample were classified in KL grade 4.
Because of batch measurement adjustments, we could
not consider reference values or cutoff points for inflam-
matory markers or adipokines, but adjusted values are
shown in Table 1.
Table 2 displays associations between Lequesne index;
demographic, radiographic, and cardiovascular risk factors;
and anthropometric measurements. Intensity of physical
exercise showed a significant inverse association with
clinical severity, and more severe KL grade was signifi-
cantly associated with Lequesne index. All anthropometric
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parameters achieved significance, with WC being the one
showing the strongest association (r = 0.404, p < 0.0001). It
is worth noting that all these anthropometric measures
were highly intercorrelated (r values 0.630–0.883). Weak,
nonsignificant trends for association were found for MetS,
obesity, and hypertension with Lequesne index (p = 0.072,
p = 0.071, and p = 0.059, respectively). Among all the in-
flammatory markers under study, only TNF-α showed a
significant association with Lequesne index after control-
ling by measurement batch (PCC 0.273, p = 0.0057). No as-
sociation with severity was found for age, KOA symptom
duration, MetS factors, dyslipidemia, or diabetes mellitus.
Among all the anthropometric measures evaluated in
a multivariate model, WC was the most strongly associ-
ated with clinical severity, accounting for an estimated
increase of 0.9 points in the Lequesne index for every
5-cm increase in WC before simultaneous evaluation
of inflammatory markers and adipokines (PCC 0.338,
p = 0.0003). Although the percentage of body fat was
also selected as a confounder according to model se-
lection criteria, it was not significantly associated to
severity in the multivariate model.
Table 3 shows the association between the Lequesne
index and each adipokine for three different settings: in
a univariate fashion (estimates were adjusted only by
measurement batch), adjusting by selected confounders
(a different model was fitted for each compound), and
controlling by selected confounders as well as the rest of
the adipokines (a unique model was fitted to perform all
estimations). This sequential analysis allowed us to
evaluate the relationship between each adipokine and
OA severity while assessing the effect of confounders in
these associations. Variables selected for adjustment of
the adipokines’ effects included age, KL grade, time from
recruitment to date of radiologic assessment, KOA
symptom duration, WC, percentage of body fat, physical
exercise, TNF-α, and batch of ELISA measurements.
Regarding adipokines, leptin showed a significant
strong association according to the univariate-like
analysis (PCC 0.413, p < 0.0001) (Fig. 1a). However,
significance was highly attenuated after adjustment by
confounding variables, especially after inclusion of
WC, as revealed by a detailed examination of the model
(see Additional file 3: Table S2).
Similarly, in univariate analysis, resistin showed a
highly significant correlation with Lequesne index (PCC
0.324, p = 0.0005) that was markedly reduced after
adjustment by confounders. Nevertheless, resistin became
the strongest positively associated adipokine when all of
them were jointly evaluated (PCC 0.265, p = 0.0184)
(Fig. 1b; see Additional file 3: Table S3).
A nonsignificant association between visfatin and
Lequesne index in the univariate analysis or after adjust-
ment by selected confounders was found. Nevertheless,
Table 1 Demographic variables, cardiovascular risk factors,
radiographic and clinical severity, anthropometric measurements,
inflammatory markers, and adipokines levels in synovial fluid
Variables Category Median (IQR) or n (%)
Age, years 68.8 (11.1)
KOA symptoms
duration, months
50.0 (73.0)
Tobacco exposure Yes 8 (7.0 %)
Physical exercise Never 53 (46.1 %)
Occasional 28 (24.3 %)
Regular 34 (29.6 %)
Cardiovascular
risk factors
DM 12 (10.4 %)
DL 55 (47.8 %)
Obesity 65 (56.5 %)
HT 63 (54.8 %)
Crit MetS 0 10 (8.7 %)
1 28 (24.3 %)
2 31 (27.0 %)
3 32 (27.8 %)
4 14 (12.2 %)
MetS 47 (40.9 %)
Anthropometric
measurements
Body fat, % 41.8 (6.5)
BMI, kg/m2 30.5 (6.4)
Weight, kg 72.2 (13.5)
WC, cm 100.5 (14.5)
HC, cm 107.0 (14.0)
WHR 0.91 (0.09)
Radiographic severity KL grade 1 15 (13.1 %)
2 48 (41.7 %)
3 48 (41.7 %)
4 4 (3.5 %)
Clinical severity Lequesne index 14.0 (5.0)
Inflammatory
markers in SFa
IL-6, pg/ml 106.0 (302.6)
TNF-α, pg/ml 10.2 (8.0)
hs-CRP, mg/ml 0.91 (0.76)
Adipokines in SFa Leptin, pg/ml 42079.4 (29566.0)
Adiponectin, ng/ml 1734.8 (1352.5)
Resistin, pg/ml 2225.7 (2205.8)
Visfatin, ng/ml 1.5 (1.2)
Osteopontin, ng/ml 57.7 (83.2)
Omentin, pg/ml 3396.0 (3550.4)
Chemerin, ng/ml 102.7 (82.5)
Abbreviations: DM Diabetes mellitus, DL Dyslipidemia, HT Hypertension, Crit MetS
Number of individual criteria for metabolic syndrome, MetS Metabolic syndrome,
KL Kellgren-Lawrence scale, BMI Body mass index, WC Waist circumference,
HP Hip circumference, WHR Waist-to-hip ratio. IL-6 Interleukin 6, SF Synovial fluid,
TNF-α Tumor necrosis factor-α, hs-CRP High-sensitivity C-reactive protein
Medians and interquartile ranges (IQR) were used to describe continuous
variables; categorical data were summarized using absolute frequencies (n)
and percentages (%)
aLevels of inflammatory markers and adipokines in synovial fluid were
adjusted by measure round
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an inverse association became evident after inclusion of
all adipokines in the model (PCC −0.298, p = 0.0075)
(Fig. 1c). A detailed study of the model showed that this
effect reached statistical significance after controlling for
resistin levels (Fig. 2) (see Additional file 3: Table S4).
Osteopontin achieved a significant correlation with
Lequesne index in the univariate and adjusted models
(PCC 0.350, p = 0.0002, and PCC 0.245, p = 0.0187, re-
spectively) (Fig. 1d). However, only a trend for associ-
ation remained when it was evaluated in the complete
model (PCC 0.197, p = 0.0824) (see Additional file 3:
Table S5).
No relationship between adiponectin or omentin and
Lequesne index was observed in the univariate or adjusted
analyses, but a nonsignificant trend arose for both when
the rest of the adipokines were included in the model
(PCC 0.212, p = 0.0612, and PCC 0.216, p = 0.0562,
respectively). Finally, chemerin showed no association
with KOA clinical severity in any of the settings studied.
Regarding inflammatory markers, TNF-α showed a
weak but statistically significant association with Lequesne
index, which remained after adjustment by confounders
(PCC 0.249, p = 0.0162). Nonetheless, there was no inde-
pendent association between Lequesne index and TNF-α
when controlled by the effect of adipokines. Specifically, a
detailed study of the complete model revealed that TNF-α
did not show an independent association for osteopontin
and resistin (see Additional file 3: Table S1).
Last, the covariates that retained a significant associ-
ation with Lequesne index after the inclusion of TNF-α
and the adipokines in the complete model were physical
exercise, with an estimated decrease of nearly 3 Lequesne
index points among patients doing regular exercise versus
sporadic or no exercise (p = 0.0016); WC, which showed
an increase of 0.5 Lequesne index points for every 5-cm
increment (PCC 0.230, p = 0.0419); and radiographic se-
verity, with an average increase of 1 point in the Lequesne
index for every change in KL grade (p = 0.0265) (see
Additional file 3: Tables S6, S7, and S10).
Discussion
In this study, we evaluated the relationship between clin-
ical severity of KOA as measured by the Lequesne index
and different adipokines and inflammatory markers in
synovial fluid, anthropometric measurements, cardiovas-
cular risk factors, and MetS in a cohort of women with
KOA and persistent joint effusion. Our results show
that, among all the adipokines measured, high levels of
resistin, leptin, and osteopontin were related to greater
clinical severity of KOA. Of these, resistin showed an
effect independent from all adjusted variables; the asso-
ciation with leptin was attenuated by WC and was elimi-
nated by TNF-α, while the effect of osteopontin did not
remain once the rest of the adipokines were evaluated
Table 2 Associations between Lequesne index and demographic,
radiographic, and cardiovascular risk factors; anthropometric
measurements; and inflammatory markers
Category Median or correlation
(95 % CI)
p Value
Age 0.118 (−0.078, 0.313) 0.2090
KOA symptom
duration (months)
−0.008 (−0.178, 0.176) 0.9345
Tobacco exposure No 14.0 (13.0–15.0) 0.0608
Yes 12.5 (7.0–15.0)
Physical exercise Never 15.0 (13.0–16.0) 0.0401
Occasional 14.0 (12.0–16.0)
Regular 13.0 (10.0–14.0)
Radiographic severity
(KL grade)
1 13.0 (9.0–15.0) 0.1721
2 13.0 (12.0–15.0)
3–4a 14.0 (13.0–16.0)
DM Yes 13.5 (11.0–18.0) 0.7480
No 14.0 (13.0–15.0)
DL Yes 14.0 (12.0, 16.0) 0.8551
No 14.0 (13.0–15.0)
Obesity Yes 14.0 (13.0–16.0) 0.0705
No 13.0 (12.0–15.0)
HT Yes 14.0 (13.0–16.0) 0.0589
No 13.0 (12.0–14.0)
MetS Yes 15.0 (13.0–16.0) 0.0722
No 13.0 (12.0–14.0)
Crit MetS 0 12.5 (9.0–16.0) 0.1490
1 14.0 (13.0–15.0)
2 13.0 (11.0–14.0)
3 15.5 (14.0–17.0)
4 12.5 (10.0–18.0)
Percent body fat 0.243 (0.062–0.422) 0.0088
BMI 0.277 (0.097–0.435) 0.0027
Weight 0.249 (0.082–0.407) 0.0072
WC 0.404 (0.237–0.567) <0.0001
HC 0.252 (0.078–0.412) 0.0065
WHR 0.221 (0.026–0.392) 0.0177
IL-6 0.146 (−0.045, 0.327) 0.1259
TNF-α 0.273 (0.078–0.448) 0.0057
hs-CRP 0.139 (−0.051, 0.320) 0.1429
Definition of abbreviations: KL Kellgren-Lawrence scale, DM Diabetes mellitus,
DL Dyslipidemia, HT Hypertension, Crit MetS Number of individual criteria
for metabolic syndrome, MetS Metabolic syndrome, BMI Body mass index,
WC Waist circumference, HP Hip circumference, WHR Waist-to-hip ratio,
IL-6 Interleukin 6, TNF-α Tumor necrosis factor-α, hs-CRP High-sensitivity
C-reactive protein
Correlations for continuous variables, medians for groups and their corresponding
95 % confidence (95 % CI) are shown. The partial correlation coefficient after
adjustment by measure round was used to assess associations for IL-6, TNF-α,
and hs-CRP. Spearman’s correlation coefficient is shown for the rest of the
continuous measures
aBecause only four patients were classified as KL grade 4, KL grades 3 and 4
were combined in one category
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simultaneously. In addition, high levels of visfatin were
found to be associated with lesser clinical severity for pa-
tients with similar levels of resistin. Regarding the rest of
the clinical parameters, only WC among all anthropo-
metric measurements was independently associated with
Lequesne index score. Radiographic damage was also
independently associated with clinical severity, while
intensity of physical exercise was inversely related to
Lequesne index score.
In our opinion, this cohort of patients is very homoge-
neous and has four distinctive features compared with
previous studies. First, all patients in our sample had
synovial effusion, which is usually considered an inflam-
matory feature, and this differentiates our study from
others [25–27]. Second, our patients were very symp-
tomatic in contrast to other series in which symptomatic
status was not evaluated and only radiographic or
diagnostic criteria were assessed [28–30]. Third, most
patients were not in the final stage of the disease, with
more than 50 % in KL grade 1 or 2, in contrast to other
series where most patients had advanced disease or were
undergoing prosthetic surgery. Fourth, all patients were
women. As previous researchers have reported, there are
differences regarding pain evaluation or anthropometric
measures related to gender [31].
Resistin was the adipokine most clearly associated with
the Lequesne index in our study. A previous study
showed an association between Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC)
total score and synovial fluid resistin, but, in contrast to
our study, it was conducted with patients undergoing
arthroscopic lavage and was not focused on patients
with joint effusion, and the relationship with Lequesne
index was not evaluated [15]. Other authors have re-
ported an association between resistin and IL-6 with
severity scores of KOA [32], but patients were in a final
stage of the disease, and the synovial fluid was collected
during surgery. In contrast, other authors who have
evaluated the role of synovial fluid IL-6 and TNF-α in
patients with KOA stages similar to those of our sample
found no relationship between IL-6 and WOMAC sub-
scales of pain or disability [33]. Thus, the role of resistin
in KOA clinical severity was not explained by the pos-
sible association with IL-6, which might be more import-
ant in more advanced disease [34].
Our analyses seem to unveil a probable protective
effect of visfatin in KOA regarding clinical severity.
Visfatin has been related to cartilage degradation [17],
and synovial fluid levels of visfatin have been associated
with hip pain, but not with knee pain [35]. In contrast to
our study, in these studies all patients were classified in
KL grade 3 or 4 and undergoing joint arthroplasty. In
vitro studies had evaluated the relationship between
visfatin and different pain mechanisms in OA, such as
nerve growth factor stimuli and nicotinamide phosphori-
bosyltransferase enzyme activity [36, 37]. Nevertheless,
to our knowledge, its association with OA severity has
not been clinically evaluated. Interestingly, the associ-
ation with visfatin becomes evident only when con-
trolled by TNF-α and the rest of the adipokines in the
analysis, especially resistin. We do not know the mech-
anism behind this effect, but this result suggests the exist-
ence of interrelationships among these compounds
regarding their role in KOA clinical severity. Overall, these
findings may provide new and promising hypotheses for
exploration in future research into how inflammation is ac-
tivated or blocked by visfatin. In this respect, it might be
interesting to assess the association of synovial fluid visfatin
levels with anti-inflammatory factors, such as IL-10 [38].
Previous studies have related synovial fluid osteopon-
tin with KOA severity [16, 39], although the patients dif-
fered from those in our series because of synovial fluid
Table 3 Association between adipokines and Lequesne index in three different settings
Univariate effects Adjusted effects Multivariate model
PCC (95 % CI) p Value PCC (95 % CI) p Value PCC (95 % CI) p Value
Leptin 0.413 (0.238–0.561) <0.0001 0.182 (−0.033, 0.382) 0.0891 0.192 (−0.036, 0.402) 0.0897
Adiponectin 0.035 (−0.155, 0.222) 0.7170 0.134 (−0.078, 0.334) 0.2027 0.212 (−0.016, 0.419) 0.0612
Resistin 0.324 (0.143–0.483) 0.0005 0.179 (−0.031, 0.375) 0.0875 0.265 (0.040–0.464) 0.0184
Visfatin 0.066 (−0.125, 0.252) 0.4915 −0.179 (−0.374, 0.032) 0.0886 −0.298 (−0.492, −0.077) 0.0075
Osteopontin 0.350 (0.172–0.505) 0.0002 0.245 (0.037–0.432) 0.0187 0.197 (−0.032, 0.406) 0.0824
Omentin 0.013 (−0.179, 0.204) 0.8925 0.173 (−0.040, 0.371) 0.1028 0.216a (−0.012, 0.422) 0.0562a
Chemerin 0.071 (−0.124, 0.260) 0.4674 0.037 (−0.179, 0.249) 0.7327 0.012 (−0.215, 0.239) 0.9133
For univariate effects, adipokine associations were assessed separately, adjusting their effects by measurement batch only. For adjusted effects, estimation of
adipokine effects was additionally adjusted by potential confounders: age, knee osteoarthritis symptom duration, Kellgren-Lawrence grade (divided into three
categories: 1, 2, and 3 + 4 combined), time from recruitment to radiology, waist circumference, percentage of body fat, physical exercise, and tumor necrosis factor
α. In the multivariate model, effects were simultaneously estimated using a single model that included previous confounders and all adipokines except omentin
(due to high collinearity observed with adiponectin: partial correlation coefficient [PCC] 0.792)
aMultivariate association for omentin was assessed in an analogous model in which adiponectin was excluded. The PCC after adjustment by measure round was
used to assess associations between Lequesne index and adipokines
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presence and KOA stage. In our study, osteopontin
showed a clear association with clinical KOA severity
that decreased when adjusted by other adipokines, again
suggesting the existence of biological or clinical interre-
lationships between adipokines. An interaction between
osteopontin and resistin has been shown in vascular dis-
ease [40], and it is possible that synovial osteopontin
could also be controlled by other adipokines in KOA or
that they could share mechanisms of action.
A relationship between leptin and clinical severity in
knee OA has already been reported [35, 41], but, to our
knowledge, this is the first study where synovial leptin
has been studied simultaneously with a significant
number of adipokines. After proper control by WC, the
association with leptin was highly attenuated and lost
statistical significance when controlled by TNF-α.
Interaction between leptin and BMI in knee OA has
been described previously using serum samples and
related to radiologic KOA, but clinical severity was
not evaluated, and this study was not controlled by
the presence of inflammatory features such as joint
effusion [42]. Leptin and anthropometric measure-
ments may share pathways influencing clinical severity
in KOA, but our results could indicate that WC may
have a more important association than leptin in patients
with joint effusion.
Fig. 1 Scatterplots showing significant associations between adipokines and knee osteoarthritis severity: effect of leptin on Lequesne index score in
the univariate setting (adjusted by round of measurement only (a), association for resistin (b), and visfatin (c) independently of clinical, anthropometric,
metabolic, and inflammatory factors as well as the rest of the adipokines; association between Lequesne index and osteopontin after adjustment by
clinical, anthropometric, metabolic, and inflammatory factors, but not the rest of the adipokines (d)). In all cases, values were corrected for confounders
using the corresponding linear model. Adipokine values were drawn in the scale of the corresponding Taylor transformation. Labels along x-axes
are shown in the original scale of the adipokines. PCC Partial correlation coefficient, pv Association p value according to F-test derived from the
linear model
Calvet et al. Arthritis Research & Therapy  (2016) 18:207 Page 7 of 11
Regarding resistin, visfatin, leptin, and osteopontin, it
is important to highlight that when a model excluding
anthropometric measures or inflammatory factors was
applied (see Additional file 3: Tables S8 and S9), the as-
sociation of clinical severity with resistin and visfatin
persisted, suggesting that their effects were not com-
pletely explained by obesity or TNF-α. The association
between Lequesne index and leptin was highly increased
in the two models when the effect of leptin was not con-
trolled by anthropometric or inflammatory variables, indi-
cating that the pathway of leptin in clinical severity could
be shared by TNF-α and obesity. The relationship of clin-
ical severity and osteopontin was higher when not con-
trolled by anthropometric measures, but it was attenuated
when not controlled by TNF-α, indicating a possible com-
mon pathway between obesity and osteopontin [43].
A nonsignificant trend toward an association between
adiponectin and omentin with Lequesne index was ob-
served when other adipokines were considered. Adiponec-
tin has been found to be associated with inflammatory
synovial parameters, but not with clinical severity [12, 44].
Researchers in one previous study found that synovial
fluid omentin was associated with less pain and disability
as measured by WOMAC but that it was not controlled
by other adipokines [45]. One important deduction from
our results is that, in order to evaluate the effect of adipo-
kines properly, as many of them as possible should be
assessed together and controlled by anthropometric vari-
ables and inflammatory markers.
The association of Lequesne index with TNF-α remained
significant after controlling for clinical, anthropometric,
and metabolic factors. Nevertheless, this association
did not appear to be independent from the effect of
adipokines, especially ostepontin and resistin. In a
previous study with a group of patients comparable
to ours, investigators found a relationship between
TNF-α, pain, and disability as measured using WOMAC
subscales, but it was not controlled by other adipokines
[33]. Further work might be required to unveil the
role of TNF-α in clinical KOA severity and its relationship
to adipokines [29].
Among all anthropometric measurements, WC was
the most strongly associated with clinical severity. Dif-
ferent anthropometric measurements have been related
to KOA prevalence in prior studies, and their relation-
ship to Lequesne index has been described previously
[30, 46, 47]. WC could represent a better measurement
of visceral and abdominal fat, which is known to be re-
lated to low-grade systemic inflammation [9, 10], and
could have more relevance in our group of patients with
local inflammation.
Several studies have connected physical exercise with
less pain and disability in KOA. It has been suggested
that this effect could be related to better muscle strength
Fig. 2 Scatterplot of visfatin vs Lequesne index after stratification by resistin levels. Values were corrected for confounders, except for resistin,
using the complete model (multivariate model in Table 3). Levels of resistin were defined using tertiles after correction of their values by measurement
round using the complete model. PCC Partial correlation coefficient, 95 % CI PCC interval at 95 % confidence, Interact. pv p Value for the interaction
between visfatin and resistin according to an F-test derived from the linear model
Calvet et al. Arthritis Research & Therapy  (2016) 18:207 Page 8 of 11
[48]. In our study, physical exercise was associated with
a better Lequesne index score.
Cross-sectional studies are not the best way to evaluate
radiographic implication in pain, but disability may be
evaluated. In our study, the relationship between
radiologic and clinical severity was assessed in a
group of female patients with KOA with effusion. We
used the Lequesne index, in which disability has a
relative weight greater than that of pain, and we
found that radiographic severity was associated with
Lequesne index, in accordance with previous studies
[49], although they were not conducted with patients
with KOA with synovial effusion.
Cardiovascular risk factors and MetS have been associ-
ated with the presence of OA [6, 7], and in some cases with
higher pain levels, especially in patients with diabetes. As-
sociation between MetS and KOA was not evaluated in
this study, but MetS and its individual components were
very prevalent in our patients. No individual cardiovascular
risk factor was related to Lequesne index, although hyper-
tension and obesity showed a trend toward association.
Neither MetS nor the addition of its individual compo-
nents was significantly associated with clinical severity in
our group of female patients with KOA on the basis
of synovial fluid measurements. It is important to
highlight that the association between MetS and OA
may change depending on the diagnostic criteria used,
so it would be important to standardize criteria for
future studies [46, 50].
The main limitation of our study arises from its cross-
sectional nature and therefore its inability to establish
causality. Accordingly, conclusions can be drawn only in
terms of associations. A selection bias toward greater
disease severity could exist, as all patients were referred
from primary care or other specialists to our rheumatol-
ogy unit and were systematically included. These results
warrant replication in other groups of patients with
KOA, such as men or patients with lesser WC, BMI, or
pain. In this study, information on OA at other sites,
which could interfere with the evaluation of clinical se-
verity, was not adequately collected to be analyzed.
There may be technical concerns regarding measures in
synovial fluid that are inherent to ELISA technology;
nonnegligible effects associated with time of measure-
ment were identified. For this reason, we corrected these
measures by round in the statistical models to make
values of adipokines and inflammatory markers totally
comparable across samples. Although this correction re-
sulted in reliable estimations of association for these
measures, it was not possible to establish either their
real range of variability or meaningful cutoffs that could
be extrapolated to other datasets.
A remarkable strength of this work is that a highly
homogeneous sample of patients with KOA was studied,
which increased the statistical power to detect associations
of a moderate magnitude. Another strength is the avail-
ability of patient information relevant to outcome,
which makes this study singular among others, as it
allowed for a simultaneous analysis of a high number
of clinical, anthropometric, metabolic, and inflammatory
factors and their relationship to up to seven different
adipokines.
Conclusions
To the best of our knowledge, this is the first study of
the relationship between seven adipokines in synovial
fluid and clinical severity of KOA controlled by three
inflammatory markers in synovial fluid, anthropometric
measurements, and metabolic factors. Resistin and visfatin
were independently associated with the Lequesne index.
Leptin and osteopontin were associated with clinical
severity of KOA until all adipokines were evaluated
together, pointing to potential biologic interrelationships
among them. Therefore, simultaneous study of different
adipokines should be recommended in future research.
Further evaluation of different adipokines both in synovial
fluid and in serum in future studies and in different popu-
lations, such as male patients, patients without synovial ef-
fusion, or patients with lower levels of pain are warranted.
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